• KOL
    • KOLs Community
    • Adipose
    • Adipose Tissue
    • David Araújo‐vilar
    • David Araújo‐Vilar

      David Araújo‐Vilar

      UETeM-Molecular Pathology Group. Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, Spain; ...

       

       

      KOL Resume for David Araújo‐Vilar

      Year
      2022

      UETeM-Molecular Pathology Group. Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, Spain;

      Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela, 15706, Santiago de Compostela, Spain

      2021

      UETeM-Molecular Pathology Group, Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain;, (S.S.-I.);, (A.F.-P.);, (S.C.-G.);, (Á.H.-A.)

      Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain

      2020

      Endocrinology and Nutrition Division, Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain

      2019

      Department of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain

      2018

      UETeM-Molecular Pathology Group. Department of Medicine, IDIS-CIMUS, University of Santiago de Compostela, Spain

      2017

      Department of Medicine, UETeM, CIMUS School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain.

      University of Santiago de Compostela UETeM‐Molecular Pathology Group Santiago de Compostela Spain

      2016

      Complexo Hospitalario de Santiago de Compostela, University of Santiago, Santiago, Spain

      2015

      Servicio de Endocrinoloxía e Nutrición, Complexo Hospitalario Universitario de Santiago de Compostela, Departamento de Medicina, Instituto de Investigaciones Sanitarias de Santiago-Universidade de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain

      2014

      Servicio de Endocrinoloxía e Nutrición, Complexo Hospitalario Universitario de Santiago de Compostela, Departamento de Medicina, Instituto de Investigaciones Sanitarias de Santiago-Universidade de Santiago de Compostela, Santiago de Compostela, A Coruña, España

      UETeM-Molecular Pathology Group, Department of Medicine, IDIS-CIMUS-Facultade de Medicina, University of Santiago de Compostela, Avda de Barcelona s/n, 15707 Santiago de Compostela, Spain

      2013

      Department of Medicine, School of Medicine and CIMUS Biomedical Research Institute, University of Santiago de Compostela-IDIS, Santiago de Compostela, Spain

      2012

      Division of Endocrinology and Nutrition, Hospital Clínico Universitario de Santuago de Compostela, Tv Choupana s/n, 15706 Santiago de Compostela, Spain

      Thyroid and Metabolic Diseases Unit (U.E.T.eM.), Department of Medicine, University of Santiago de Compostela

      2010

      Servicio de Endocrinoloxía e Nutrición, Complexo Hospitalario Universitario de Santiago de Compostela, Spain

      2008

      University Clinical Hospital of Santiago de Compostela

      2007

      Unidade de Enfermedades Tiroideas e Metabólicas (F.P., D.A.-V., O.P.-G., L.D.-G., J.L.-A.), Molecular Medicine Unit, Complejo Hospitalario Universitario de Santiago, Servicio Galego de Saude, University of Santiago de Compostela, Santiago de Compostela 15075, Spain

      2006

      Departamento de Medicina,

      2004

      Division of Endocrinology and Nutrition, Hospital Clı́nico Universitario de Santiago, Department of Medicine, School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain

      2003

      Servicio de Endocrinoloxía e Nutrición, Departamento de Medicina, University of Santiago de Compostela, Spain.

      Division Of Endocrinology and Nutrition, Hospital Clínico Universitario de Santiago de Compostela, Department of Medicine, School of Medicine, University of Santiago de Compostela, and

      1999

      Service of Endocrinology and Nutrition and the Department of Medicine, Complejo Hospitalario Universitario de Santiago de Compostela, School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain

      1998

      Service of Endocrinology and Nutrition, Complejo Hospitalario Universitario de Santiago, School of Medicine, University of Santiago de Compostela, r/Galeras s/n, 15705 Santiago de Compostela, Spain

      1997

      Sheikh Rashid Diabetes Unit, Radcliffe Infirmary, Oxford, UK

      Endocrinology Service of the University Hospital, School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain

       

       

      David Araújo‐Vilar: Influence Statistics

      Sample of concepts for which David Araújo‐Vilar is among the top experts in the world.
      Concept World rank
      bscl2 transcript #2

       

      Prominent publications by David Araújo‐Vilar

      KOL-Index: 11840

      OBJECTIVE: Toxic thyroid adenoma (TA) is a common cause of hyperthyroidism. Mutations in the TSH receptor (TSHR) gene, and less frequently in the adenylate cyclase-stimulating G alpha protein (GNAS) gene, are well established causes of TA in Europe. However, genetic causes of TA remain unknown in a small percentage of cases. We report the first study to investigate mutations in TSHR, GNAS, protein kinase, cAMP-dependent, regulatory, type I alpha (PRKAR1A) and RAS genes, in a large series ...

      Known for Toxic Thyroid | Mutations Tshr | Gnas Gene | Protein Kinase | Tsh Receptor
      KOL-Index: 10842

      CONTEXT: Steroid 11beta-hydroxylase (CYP11B1) deficiency (11OHD) is the second most common form of congenital adrenal hyperplasia (CAH). Cases of nonclassic 11OHD are rare compared with the incidence of nonclassic 21-hydroxylase deficiency.

      OBJECTIVE: The aim of the study was to analyze the functional consequences of seven novel CYP11B1 mutations (p.M88I, p.W116G, p.P159L, p.A165D, p.K254_A259del, p.R366C, p.T401A) found in three patients with classic 11OHD, two patients with nonclassic ...

      Known for Functional Consequences | Cyp11b1 Mutations | Nonclassic 11ohd | Hydroxylase Deficiency | Common Form
      KOL-Index: 10164

      PurposeThe purpose of this study is to summarize the effectiveness and safety of metreleptin in patients with congenital or acquired generalized lipodystrophy.MethodsPatients (n = 66) aged ≥6 months had lipodystrophy, low circulating leptin, and ≥1 metabolic abnormality (diabetes mellitus, insulin resistance, or hypertriglyceridemia). Metreleptin dose (once or twice daily) was titrated to a mean dose of 0.10 mg/kg/day with a maximum of 0.24 mg/kg/day. Means and changes from baseline to ...

      Known for Generalized Lipodystrophy | Tgs Month | Metreleptin Patients | Liver Volume | Decrease Hba1c
      KOL-Index: 9335

      BACKGROUND: Lipodystrophies are a heterogeneous group of diseases characterized by abnormal fat distribution. Familial partial lipodystrophy 2 (FPLD2) is due to mutations in the LMNA gene. Previous studies have suggested that LMNA mutations 5' to the nuclear localization signal (NLS) are more likely to underlie laminopathies with cardiac or skeletal muscle involvement, while mutations 3' to the NLS are more likely to underlie lipodystrophy and progeroid syndromes.

      OBJECTIVE: To study the ...

      Known for Lmna Gene | Insulin Resistance | Partial Lipodystrophy | Hypertrophic Cardiomyopathy | Body Composition
      KOL-Index: 8557

      To establish the relative importance of insulin sensitivity and glucose effectiveness during exercise using Bergman's minimal model, 12 nontrained healthy subjects were studied at rest and during 95 minutes of moderate exercise (50% maximum oxygen consumption [VO2max]). Each subject underwent two frequently sampled intravenous glucose tolerance tests (FSIGTs) for 90 minutes, at rest (FSIGTr) and during exercise (FSIGTe). Plasma glucose, insulin, and C-peptide were determined. Insulin ...

      Known for Glucose Effectiveness | Insulin Sensitivity | Bergmans Minimal Model | Tolerance Test | Adult Blood
      KOL-Index: 8400

      PurposeTo evaluate the effects of metreleptin in patients with partial lipodystrophy (PL).MethodsPatients aged ≥ 6 months with PL, circulating leptin < 12.0 ng/mL, and diabetes mellitus, insulin resistance, or hypertriglyceridemia received metreleptin doses (once or twice daily) titrated to a mean of 0.124 mg/kg/day. Changes from baseline to month 12 in glycated hemoglobin (HbA1c) and fasting serum triglycerides (TGs; co-primary endpoints), fasting plasma glucose (FPG), and liver volume ...

      Known for Partial Lipodystrophy | Metreleptin Patients | Insulin Resistance | Hba1c Fasting | Primary Endpoints
      KOL-Index: 8132

      Familial partial lipodystrophy are Mendelian disorders involving abnormal body fat distribution and insulin resistance. The current classification includes the Köbberling syndrome (type 1 familial partial lipodystrophy), characterized by fat loss in the lower limbs and abnormal fat accumulation in other areas. Type 1 familial partial lipodystrophy appears to be heritable, but little is known about it, including putative contributing mutations. We aimed to characterize this syndrome ...

      Known for Partial Lipodystrophy | Insulin Resistance | Lower Limbs | Type 1 | Fat Loss
      KOL-Index: 7895

      BACKGROUND: Type 2 familial partial lipodystrophy (FPLD2) is characterised by loss of fat in the limbs and buttocks and results from mutations in the LMNA gene.

      AIM: To evaluate the role of several genes involved in adipogenesis in order to better understand the underlying mechanisms of regional loss of subcutaneous adipose tissue (scAT) in patients with FPLD2.

      METHODS: In total, 7 patients with FPLD2 and 10 healthy control participants were studied. A minimal model was used to calculate ...

      Known for Subcutaneous Adipose Tissue | Familial Partial | Type 2 | Lmna Gene | Insulin Sensitivity
      KOL-Index: 7798

      The effects of the acute insulin response to glucose (AIRg), insulin sensitivity (SI), and glucose effectiveness at zero insulin (GEZI) on intravenous glucose tolerance were studied in 94 non elderly healthy subjects with a wide range of body mass index (BMI). Conrad's coefficient of glucose assimilation (KG) was calculated between 10 and 19 minutes of an intravenous glucose tolerance test. Both SI and GEZI were estimated using Bergman's minimal model. AIRg was calculated as the area ...

      Known for Intravenous Glucose | Acute Insulin Response | Insulin Sensitivity | Body Mass Bmi | 10 Minutes
      KOL-Index: 7674

      OBJECTIVE: Lipodystrophy syndromes are extremely rare disorders of deficient body fat associated with potentially serious metabolic complications, including diabetes, hypertriglyceridemia, and steatohepatitis. Due to their rarity, most clinicians are not familiar with their diagnosis and management. This practice guideline summarizes the diagnosis and management of lipodystrophy syndromes not associated with HIV or injectable drugs.

      PARTICIPANTS: Seventeen participants were nominated by ...

      Known for Lipodystrophy Syndromes | Practice Guideline | Metabolic Complications | Diagnosis Management | Genetic Testing
      KOL-Index: 7627

      OBJECTIVE: To detect common as well as rare and novel CYP21A mutations in 21-hydroxylase deficiency patients. To estimate the distribution of mutations and compare them with other European studies. To construct haplotypes linked to a recurrent novel mutation.

      DESIGN: Genetic analysis by sequencing the entire CYP21A2 gene plus Southern blot.

      PATIENTS: A total of 138 unrelated Spanish patients: 122 nonclassical forms (NCF) and 16 classical forms (CF) were studied.

      RESULTS: Among the 266 ...

      Known for Mutated Alleles | Gene Frequency | Southern Blot | Single Nucleotide | 21 Hydroxylase
      KOL-Index: 7385

      To evaluate the factors that determine the worsening of intravenous glucose tolerance in subjects at high risk for developing non-insulin-dependent diabetes mellitus (NIDDM), 15 glucose-tolerant offspring of NIDDM patients and 21 control subjects were studied. Each subject underwent a frequently sampled intravenous glucose tolerance (FSIGT) test. The intravenous glucose tolerance index (K(G) index) was calculated between minutes 10 and 40 of a FSIGT test. Insulin sensitivity (S(I)), ...

      Known for Insulin Sensitivity | Glucose Effectiveness | Diabetes Mellitus | Tolerance Test | Crosssectional Study
      KOL-Index: 6628

      The objective of our research was to identify the mathematical model that would best define the relationship between obesity, insulin resistance (IR), and beta-cell function. Eighty-seven healthy subjects with a wide range of body mass index (BMI) were studied. Insulin sensitivity (IS) was calculated using Bergman's minimal model. Acute insulin response (AIRg) was calculated as the secretion of insulin during the first 10 minutes following a glucose bolus. IS x AIRg was used as an index ...

      Known for Insulin Resistance | Minimal Model | Body Mass Bmi | Cell Function | Crosssectional Study
      KOL-Index: 6415

      AimLipodystrophy syndromes are rare heterogeneous disorders characterized by deficiency of adipose tissue, usually a decrease in leptin levels and, frequently, severe metabolic abnormalities including diabetes mellitus and dyslipidemia.PurposeTo describe the clinical presentation of known types of lipodystrophy, and suggest specific steps to recognize, diagnose and treat lipodystrophy in the clinical setting.MethodsBased on literature and in our own experience, we propose a stepwise ...

      Known for Patients Lipodystrophy | Adipose Tissue | Replacement Therapy Complications | Diabetes Mellitus | Fat Loss
      KOL-Index: 5989

      A variety of missense mutations in LMNA (the gene for lamin C and prelamin A) cause familial partial lipodystrophy (FPLD), a disease associated with reduced adipose tissue, particularly in the limbs. Several studies have reported that fibroblasts from FPLD subjects have an accumulation of prelamin A. Those findings were intriguing but also perplexing because many of the LMNA missense mutations associated with lipodystrophy are located in sequences distant from the sequences required for ...

      Known for Lmna Mutations | Partial Lipodystrophy | Lamin Type | Lead Accumulation | Adipose Tissue

      Key People For Adipose Tissue

      Top KOLs in the world
      #1
      Bruce M Spiegelman
      adipose tissue insulin resistance gene expression
      #2
      Philipp E Scherer
      adipose tissue insulin resistance metabolic syndrome
      #3
      Peter Arner
      adipose tissue insulin resistance fat cells
      #4
      Gökhan Siddik Hotamisligil
      insulin resistance tumor necrosis factor adipose tissue
      #5
      Jeffrey S Flier
      insulin resistance adipose tissue leptin levels
      #6
      Saverio Cinti
      adipose tissue brown adipocytes insulin resistance

      David Araújo‐Vilar:Expert Impact

      Concepts for whichDavid Araújo‐Vilarhas direct influence:Adipose tissue,  Insulin resistance,  Partial lipodystrophy,  Familial partial,  Minimal model,  Lmna gene,  Lipodystrophy syndromes,  Generalized lipodystrophy.

      David Araújo‐Vilar:KOL impact

      Concepts related to the work of other authors for whichfor which David Araújo‐Vilar has influence:Insulin resistance,  Adipose tissue,  Partial lipodystrophy,  Congenital adrenal hyperplasia,  Glucose effectiveness,  Lmna gene,  Pendred syndrome.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      UETeM-Molecular Pathology Group. Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, Spain; david.araujo@usc.es. | UETeM-Molecular Pathology Group, Department of Psychiatry, Radi

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.